Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Clinical trial NCT06981325 · RECRUITING

Trial details

NCT number: NCT06981325
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Basal Cell Carcinoma (BCC)First Line Treatment

Start date: 2025-08-07
Primary completion: 2028-10-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.